ValuEngine upgraded shares of Corcept Therapeutics (NASDAQ:CORT) from a sell rating to a hold rating in a research note published on Thursday morning.

CORT has been the topic of a number of other research reports. B. Riley lowered their target price on shares of Corcept Therapeutics from $30.00 to $22.00 and set a buy rating on the stock in a research note on Monday, August 13th. BidaskClub raised shares of Corcept Therapeutics from a hold rating to a buy rating in a research note on Saturday, May 19th. Cantor Fitzgerald initiated coverage on shares of Corcept Therapeutics in a research note on Thursday, August 23rd. They issued a neutral rating and a $17.00 target price on the stock. Finally, Stifel Nicolaus cut shares of Corcept Therapeutics from a buy rating to a hold rating and set a $20.00 target price on the stock. in a research note on Thursday, May 31st. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. The company has a consensus rating of Buy and a consensus target price of $21.83.

NASDAQ:CORT opened at $15.00 on Thursday. Corcept Therapeutics has a 52-week low of $11.55 and a 52-week high of $25.96. The stock has a market cap of $1.60 billion, a PE ratio of 34.09 and a beta of 1.70.

Corcept Therapeutics (NASDAQ:CORT) last posted its quarterly earnings data on Thursday, August 9th. The biotechnology company reported $0.20 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.04). Corcept Therapeutics had a return on equity of 38.53% and a net margin of 68.32%. The company had revenue of $62.31 million for the quarter, compared to the consensus estimate of $68.49 million. During the same quarter in the previous year, the firm posted $0.13 EPS. The business’s revenue for the quarter was up 75.2% compared to the same quarter last year. equities research analysts forecast that Corcept Therapeutics will post 0.6 earnings per share for the current year.

In other Corcept Therapeutics news, insider Robert S. Fishman sold 8,000 shares of the business’s stock in a transaction dated Friday, July 6th. The shares were sold at an average price of $15.09, for a total value of $120,720.00. Following the transaction, the insider now directly owns 8,000 shares in the company, valued at $120,720. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director G Leonard Baker, Jr. purchased 35,681 shares of Corcept Therapeutics stock in a transaction on Monday, August 20th. The stock was purchased at an average price of $12.92 per share, for a total transaction of $460,998.52. Following the completion of the transaction, the director now owns 876,838 shares of the company’s stock, valued at $11,328,746.96. The disclosure for this purchase can be found here. In the last three months, insiders purchased 321,159 shares of company stock worth $4,025,880 and sold 24,000 shares worth $379,760. Insiders own 15.00% of the company’s stock.

A number of large investors have recently added to or reduced their stakes in CORT. Tyers Asset Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $136,000. Asset Management One Co. Ltd. acquired a new position in Corcept Therapeutics in the first quarter valued at about $150,000. Riverhead Capital Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $155,000. Flinton Capital Management LLC acquired a new position in Corcept Therapeutics in the first quarter valued at about $173,000. Finally, Stifel Financial Corp acquired a new position in Corcept Therapeutics in the first quarter valued at about $182,000. Hedge funds and other institutional investors own 74.79% of the company’s stock.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated, a pharmaceutical company, discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and psychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery, as well as develops CLIA-validated assay to measure FKBP5 gene expression.

See Also: How to Invest in Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Corcept Therapeutics (NASDAQ:CORT)

Receive News & Ratings for Corcept Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corcept Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.